Affordability and Accessibility of Ipamorelin

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Ipamorelin is a short synthetic agonist of the growth hormone secretagogue (GHS) receptor and is recognized as one of the most selective compounds for stimulating growth hormone release. In addition to its strong selectivity, it is also relatively inexpensive, with the cost for a 5 mg vial typically staying under $100. This affordability has made ipamorelin a popular option among researchers examining the role of GHS activation in areas such as growth, muscle performance, bone density, metabolic health, and recovery from conditions like postoperative ileus. Considering its potential applications, benefits, and low cost, it is surprising that more extensive research has not been conducted to further explore and expand scientific understanding of this compound.

What Is Ipamorelin?

Ipamorelin Overview

Ipamorelin is a synthetic, highly selective agonist of the growth hormone secretagogue (GHS) receptor. It was originally developed by Novo Nordisk as a potential therapy for postoperative ileus. Structurally, it is derived from growth hormone–releasing peptide-1 (GHRP-1), which itself is a modification of ghrelin, the natural protein hormone commonly referred to as the “hunger hormone.”

Relation to Ghrelin

Ghrelin is secreted by the stomach and plays a key role in stimulating appetite. Beyond regulating food intake, ghrelin activates anterior pituitary cells to elevate both neuropeptide Y and growth hormone levels. Its physiological influence extends to learning, memory, reward pathways, energy metabolism, and circadian rhythm regulation. Ipamorelin retains some of ghrelin’s functions but with greater selectivity, making it a potentially more targeted tool for research applications.

Structure and Properties

Ipamorelin is composed of just five amino acids: Aib-His-D-2Nal-D-Phe-Lys, which makes it relatively straightforward to synthesize through recombinant techniques—contributing to its accessibility and affordability.

• Peptide Sequence: Aib-His-D-2Nal-D-Phe-Lys
• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.868 g/mol
• PubChem CID: 9831659
• CAS Number: 170851-70-4

How Ipamorelin Works

The growth hormone secretagogue receptor (GHS-R), also referred to as the ghrelin receptor, is highly expressed in the hypothalamus and anterior pituitary. Ghrelin is believed to be its natural ligand. When agonists such as ipamorelin bind to GHS-R in the anterior pituitary, they trigger the release of growth hormone (GH).

Ipamorelin is composed of the five amino acids most responsible for receptor binding within ghrelin, making it the smallest known GHS-R agonist. By targeting these binding sites, ipamorelin demonstrates remarkable selectivity, producing strong GH release with fewer off-target effects compared to other ghrelin mimetics.

In the hypothalamus, GHS-R activation also stimulates the release of neuropeptide Y (NPY), a signaling molecule involved in appetite regulation, energy balance, and pain modulation. As a result, ipamorelin not only enhances GH secretion but also influences broader physiological processes such as pain sensitivity, feeding behavior, and metabolic activity.

Postoperative Ileus

Ipamorelin was originally developed as a potential treatment for postoperative ileus (POI), a condition where the gastrointestinal tract temporarily ceases function after surgery. This disorder is particularly problematic in older patients and those with chronic illness. By stimulating appetite, gastrointestinal motility, and reducing visceral pain, ipamorelin was considered a promising candidate.

Although it advanced through Phase II clinical trials, studies found limited efficacy in treating POI. Still, the successful completion of Phase I trials confirmed ipamorelin’s safety in humans, leaving open the possibility of further clinical exploration in other therapeutic areas.

Appetite and Feeding Behavior

Due to its link with ghrelin, ipamorelin has moderate appetite-stimulating effects. Compared with other analogues like GHRP-2 and GHRP-6, its impact is weaker, but still significant. Appetite stimulation is mediated via NPY release from hypothalamic neurons. This not only increases food consumption but also shifts food preference, enhances fat storage, reduces stress and anxiety, and alleviates pain perception.

Pain Modulation

NPY release also contributes to reduced pain sensitivity. Animal studies indicate ipamorelin is especially effective at lowering visceral and neuropathic pain, sometimes by as much as twofold. These findings suggest potential therapeutic roles in irritable bowel syndrome, inflammatory bowel disease, diabetic neuropathy, degenerative disk disease, and post-stroke pain syndromes.

Bone Health

One of the most compelling areas of ipamorelin research is bone metabolism. Preclinical studies demonstrate that it promotes bone mineralization and new bone formation. In models of corticosteroid use where bone loss is a common side effect, ipamorelin not only prevented bone resorption but increased bone formation by up to fourfold.

These findings make it particularly attractive in conditions requiring long-term steroid use, as it counteracts both abnormal fat distribution and skeletal deterioration. Unlike some bone-stimulating therapies such as parathyroid hormone (PTH), ipamorelin remains effective even in glucocorticoid-treated states.

Muscle Growth and Protection

Ipamorelin supports muscle development through dual mechanisms:

1. Anabolic stimulation: By increasing GH secretion, it promotes muscle hypertrophy (cell enlargement) and hyperplasia (cell proliferation), leading to both larger and more numerous muscle fibers. 
2. Anti-catabolic effects: Ipamorelin reduces muscle breakdown, in part by attenuating corticosteroid-induced catabolism and potentially by downregulating myostatin activity. 

Through these actions, ipamorelin enhances lean tissue growth including muscle, bone, and collagen while discouraging fat accumulation.

Cardiovascular Effects of Ipamorelin

The link between ghrelin, its analogues, and cardiovascular health is complex. Studies in both cell culture and animal models suggest that ghrelin may play a protective role in the heart following myocardial infarction and other forms of cardiac injury. Evidence indicates that ghrelin, which is produced in small amounts within the vascular system, can limit scar tissue formation and reduce subsequent cardiac hypertrophy. These effects may help prevent progression to heart failure and other long-term complications.

The precise mechanisms remain under investigation. Some researchers propose that the cardioprotective properties involve modulation of communication between the autonomic nervous system and cardiac cells, while others suggest direct receptor activation leading to reduced apoptosis and inflammation. Ipamorelin, as a selective ghrelin receptor agonist, represents an appealing compound for further exploration of these pathways and may hold potential as a future therapeutic option.

Read here: LL- 37 

Sex-Based Variations in Ipamorelin Activity

Animal research, including studies in rats, mice, and pigs, indicates that ipamorelin may exert greater benefits in females than in males. One proposed explanation is the difference in baseline testosterone levels. Testosterone provides a degree of natural protection against muscle loss and reduced bone mineral density, meaning that males may already have anabolic and skeletal support that diminishes the visible impact of ipamorelin. Females, with lower testosterone levels, appear to derive more measurable benefit in terms of bone strength and muscle anabolism.

Ongoing research is investigating whether testosterone levels alone account for the observed sex differences or if other biochemical mechanisms also contribute. If additional factors are identified, they could provide valuable insight into the molecular regulation of anabolic processes.

There is also evidence suggesting ipamorelin may provide benefits during pregnancy. In cases of preeclampsia, particularly early-onset forms associated with high maternal blood pressure and increased risk of preterm delivery, patients have been found to be deficient in ghrelin. Supplementation with ghrelin analogues has been shown to stimulate blood vessel growth, potentially reducing complications. These findings raise the possibility that ipamorelin could one day be studied as a treatment option for preeclampsia, given its favorable safety and administration profile.

Cost Efficiency of Ipamorelin

Ipamorelin is notable not only for its versatility and selectivity but also for its affordability. Compared with many other growth hormone secretagogues or receptor agonists, the cost of ipamorelin is relatively low. A typical month of robust experimental use may total under $100, making it highly accessible to researchers. By contrast, monoclonal antibodies and similar experimental agents can exceed $500 per microgram. This cost advantage further enhances ipamorelin’s appeal as a candidate for both preclinical and potential clinical investigation.

Read more:  mk 677 vs ipamorelin 

REFERENCES

10. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014, doi: 10.1007/s00384-014-2030-8.
11. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–155, 2012, doi: 10.2147/JEP.S35396.
12. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998, doi: 10.1530/eje.0.1390552.
13. Alfalah, Neuropeptide Y and Related Peptides. Springer Science & Business Media, 2004.
14. N Mohammadi, T. Louwies, C. Pietra, S. R. Northrup, and B. Greenwood-Van Meerveld, “Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics,” J. Exp. Pharmacol., vol. 12, pp. 267–274, 2020, doi: 10.2147/JEP.S249747.
15. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, pp. 569–77, Jul. 2000.

Product available for research use only: